Avoiding Missed Opportunities by Analysing the Sensitivity of our Decisions
M. D. Segall, I. Yusof, and E. J. Champness, J. Med. Chem. 2016, 59, 9, 4267–4277
How can we consider the impact of the compound selection criteria we choose on the decisions we make? This article describes how identifying sensitive criteria can highlight new avenues for exploration, and assist us in avoiding missed opportunities.
Drug discovery is a multi-parameter optimisation process, in which the goal of a project is to identify compounds that meet multiple property criteria required to achieve a therapeutic objective. However, having chosen a profile of property criteria, their impact on the decisions made regarding progression of compounds or chemical series should be carefully considered. In some cases, the decision will be very sensitive to a specific property criterion and such a criterion may be artificially distorting the direction of the project; any uncertainty in the ‘correct’ value or the importance of this criterion may lead to valuable opportunities being missed. In this paper, we will describe a method for analysing the sensitivity of the prioritisation of compounds to a multi-parameter profile of property criteria. We show how the results can be easily interpreted and illustrate how this analysis can highlight new avenues for exploration.
You can download a preprint version of this article on avoiding missed opportunities & its accompanying supporting information via the buttons below. See the final published article on the journal webpage.
INTERESTED IN DRUG OPTIMIZATION?
With its comprehensive suite of integrated software, StarDrop™ delivers best-in-class in silico technologies within a highly visual and user-friendly interface. StarDrop™ enables a seamless flow from the latest data through predictive modelling to decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the drug optimisation and discovery process.